Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Pharmaceuticals, a specialty pharmaceutical company, has announced that its subsidiary, Watson Laboratories, Inc, has received approval from the FDA on its abbreviated new drug application for galantamine hydrobromide extended-release capsules, equivalent to 8mg, 16mg and 24mg.
Subscribe to our email newsletter
Galantamine hydrobromide extended-release capsules are the generic equivalent to Ortho McNeil Janssen’s Razadyne ER, galantamine HBr extended-release capsules, which are indicated for the treatment of Alzheimer’s disease. Watson intends to launch the product immediately.